OS Therapies Incorporated于2018年4月12日在特拉华州成立。该公司是一家临床阶段的生物制药公司，专注于骨肉瘤和其他实体瘤治疗的鉴定、开发和商业化。他们目前正寻求用他们的主要核心候选产品OST-HER2（也称为OST31-164）来响应新疗法的号召。他们打算用这种候选产品将他们的管道从骨肉瘤扩展到其他具有相同复发作用机制的实体瘤，包括乳腺癌、食管癌和肺癌。
董事
名称
职位
Colin Goddard
Chairman of the Board
Paul A. Romness
Founder, President, Chief Executive Officer and Director
Joacim Borg
Director
John Ciccio
Director
Theodore F. Search
Director
股东
名称
职位
Paul A. Romness
Founder, President, Chief Executive Officer and Director
Christopher P. Acevedo
Chief Financial Officer
Gerald Commissiong
Chief Business Officer
Robert G. Petit
Chief Medical Officer and Chief Scientific Officer